We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO International ConventionJune 3-6, 2019
BIO World Congress on Industrial Biotechnology and Ag TechJuly 8-11, 2019
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
February 11 - 12, 2019 | New York, New York
NanoViricides, Inc. is pioneering a unique platform of nanomedicines to treat viral diseases that we call nanoviricides®. We are advancing our first drug candidate in the HerpeCide™ program towards clinical trials. The initial indication would be for topical treatment of shingles rash. Additional drugs against HSV-1 cold sores and HSV-2 genital ulcers would follow. The Company has previously demonstrated drug candidates with strong efficacy in animal studies against a wide range of viruses including Influenzas, HIV, Dengue, Ebola, among others, attesting to robustness of the platform. The Company is also unique in that it has its own flexible multi-product c-GMP-capable manufacturing facility that can scale to several kg API per batch, enabling rapid translation to the clinic. Our platform is designed to mimic host cell receptors to the virus, thereby trapping & destroying the virus particle. This approach makes viral resistance unlikely as the resistant virus would be incompetent.